Purpura, Thrombocytopenic, Idiopathic: all 521 studies

Page 6 of 6. Open to participants first (158), then studies with results posted, then the rest; newest registration first within each.

• Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) PatientsCompletedNCT00362349Phase 3
• Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic ImpairmentCompletedNCT00359463Phase 1
• Rituximab as Second Line Treatment for ITPCompletedNCT00344149Phase 3
• Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La LoireStatus unknownNCT00331357
• Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)TerminatedNCT00244257Phase 1
• Study of the Effectiveness of Rituximab in Adults With Chronic and Severe Immune Thrombocytopenic Purpura and Candidate for a SplenectomyTerminatedNCT00225875Phase 2
• Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic PurpuraCompletedNCT00162006Phase 2
• A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan AloneWithdrawnNCT00161564Phase 2
• Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency DisordersCompletedNCT00157079Phase 3
• Efficacy and Safety of IVIG-L in ITP PatientsCompletedNCT00151840Phase 3
• Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-DCompletedNCT00128882Phase 2
• Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic PurpuraStatus unknownNCT00107913Phase 2
• SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)CompletedNCT00102739Phase 2
• AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to SplenectomyCompletedNCT00102336Phase 3
• AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to SplenectomyCompletedNCT00102323Phase 3
• Daclizumab to Treat Chronic Immune ThrombocytopeniaCompletedNCT00049725Phase 2
• Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune DiseasesStatus unknownNCT00006055Not applicable
• Phase II Study of Rituximab in Patients With Immune Thrombocytopenic PurpuraCompletedNCT00005652Phase 2
• An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune MarkersCompletedNCT00005570
• A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic PurpuraCompletedNCT00002250Phase 1
• Treatment of Autoimmune Thrombocytopenia (AITP)CompletedNCT00001630Phase 1

← Purpura, Thrombocytopenic, Idiopathic overview